Table of Contents
- Clinical trial overview
- Low-risk myelodysplastic syndromes study
- Pediatric acute promyelocytic leukemia study
- Adult acute promyelocytic leukemia study
- Main endpoints and what they mean
- Who the trials are for
- Trial phases and study design
Clinical trial overview
These studies are testing Arsenic Trioxide in different blood cancers and treatment settings.[1][2][3] The trials are focused on low-risk myelodysplastic syndromes and acute promyelocytic leukemia in children, adolescents, and adults.[1][2][3]
All three trials are interventional studies, which means researchers give a treatment and measure what happens.[1][2][3] The studies are authorised and range from early testing to later confirmatory research.[1][2][3]
Low-risk myelodysplastic syndromes study
NCT06670222 is a Phase 1 study in 24 people with low-risk myelodysplastic syndromes who failed Erythropoiesis Stimulating Agents and Luspatercept, or who are not eligible for Luspatercept.[1] This makes it a study for people who still need another treatment option after earlier care did not work well enough.[1]
The study tests oral Arsenic Trioxide in capsule form at different strengths, all given by mouth.[1] The brief summary says the first part is meant to find the dose-limiting toxicity, which is the level of side effects that may stop a dose from being used safely.[1]
The expansion part of the study looks at the erythroid response rate after 12 weeks of treatment.[1] Erythroid response means improvement in red blood cell production, which is important for patients with anemia.[1]
Pediatric acute promyelocytic leukemia study
NCT04793919 is a Phase 2 international study in 99 children and adolescents with acute promyelocytic leukemia.[2] The study looks at a treatment plan that includes Arsenic Trioxide together with other medicines, including ATRA and, in higher-risk disease, GO.[2]
The main outcome is event-free survival, or EFS.[2] EFS counts major events such as not reaching complete remission after induction therapy, not reaching molecular remission after consolidation, relapse, or death.[2]
The study aims for a 3-year EFS probability of 90% in standard-risk patients and 80% in high-risk patients.[2] This shows that the trial is not only checking whether treatment works, but also how well it keeps patients free from relapse or treatment failure over time.[2]
Adult acute promyelocytic leukemia study
2025-524810-28-00 is a Phase 3 study in 123 adult patients with acute promyelocytic leukemia.[3] It is an open-label study, which means both the researchers and the participants know what treatment is being given.[3]
This study compares a treatment plan involving QTX-2101 with Arsenic Trioxide used by intravenous infusion.[3] The brief summary says the study wants to characterize the pharmacokinetics of QTX-2101 and the treatment response at the end of Consolidation Cycle 3.[3]
The main outcomes include PK parameters, such as maximum plasma concentration and area under the curve, for Arsenic Trioxide and its metabolites.[3] PK, short for pharmacokinetics, describes how the body absorbs, moves, and clears a treatment.[3]
The study also measures molecular complete remission, defined as no detectable PML/RARA in the bone marrow by central testing using RTqPCR rules from ELN 2019 criteria.[3] This is a very deep response measure that looks for tiny signs of disease at the molecular level.[3]
Main endpoints and what they mean
The trials use different endpoints, which are the main results researchers want to measure.[1][2][3] In the myelodysplastic syndromes study, the key endpoint is dose-limiting toxicity in the first part and erythroid response after 12 weeks in the second part.[1]
In the pediatric leukemia study, the key endpoint is event-free survival at 2 years from diagnosis, with a target of 3-year EFS probabilities also described in the study summary.[2] In the adult leukemia study, the main endpoints are PK measures and molecular complete remission after treatment.[3]
These endpoints help show different parts of treatment value: safety, how well the treatment works, and whether the disease stays under control.[1][2][3]
Who the trials are for
The patient groups are different in each trial.[1][2][3] One study is for people with low-risk myelodysplastic syndromes who have not done well with earlier treatments or cannot use Luspatercept.[1]
Another study is for children and adolescents with acute promyelocytic leukemia.[2] The third study is for adults with acute promyelocytic leukemia.[3]
Trial phases and study design
The three studies cover a wide range of clinical research stages, from Phase 1 to Phase 3.[1][2][3] Phase 1 mainly looks at safety and dose finding, Phase 2 looks at treatment effect in a defined group, and Phase 3 studies the treatment in a larger adult group.[1][2][3]
The studies also use different treatment routes, including oral use and intravenous use.[1][3] In the pediatric study, Arsenic Trioxide is part of a broader treatment plan with other medicines, showing that the trial is testing combination therapy rather than Arsenic Trioxide alone.[2]
